- Trials with a EudraCT protocol (211)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
211 result(s) found for: Resistance mutation.
Displaying page 1 of 11.
EudraCT Number: 2016-003411-34 | Sponsor Protocol Number: 1200.264 | Start Date*: 2017-06-21 |
Sponsor Name:BSMO | ||
Full Title: Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation. | ||
Medical condition: cancers harbouring an EGFR mutation (excluding non-squamous non- small cell lung cancer, a registered indication), a HER2 mutation or a HER3 mutation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002633-39 | Sponsor Protocol Number: SHCS-Projekt Nr. 408 | Start Date*: 2005-02-17 |
Sponsor Name:Prof. Dr. med. Milos Opravil, Universitätsspital Zürich | ||
Full Title: Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance (a multicenter prospective clinical study within the SH... | ||
Medical condition: HIV patients with virological treatment failure due to multi-drug-resistant virus including 3TC resistance | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002601-69 | Sponsor Protocol Number: CA180-013 | Start Date*: 2005-01-25 |
Sponsor Name:Bristol Myers Squibb International Corporation | ||
Full Title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Ima... | ||
Medical condition: Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) SE (Completed) FI (Completed) GB (Completed) IE (Completed) IT (Completed) BE (Completed) ES (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006958-31 | Sponsor Protocol Number: 2021/3401 | Start Date*: 2022-05-24 |
Sponsor Name:Gustave Roussy | ||
Full Title: An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | ||
Medical condition: Locally-advanced and unresectable or metastatic non-small-cell lung cancer with KRAS G12C mutation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000290-84 | Sponsor Protocol Number: GESIDA11820 | Start Date*: 2021-04-26 |
Sponsor Name:Seimc-Gesida Foundation | ||
Full Title: Virologic Outcomes of Lamivudine/Dolutegravir in Virologically suppressed subjects with Expected or confirmed Resistance to Lamivudine (VOLVER study). | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002285-23 | Sponsor Protocol Number: POETIG | Start Date*: 2017-01-18 | |||||||||||
Sponsor Name:Universitaetsklinikum Essen | |||||||||||||
Full Title: Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POna... | |||||||||||||
Medical condition: gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001335-12 | Sponsor Protocol Number: D5160C00030 | Start Date*: 2016-05-12 |
Sponsor Name:Hellenic Oncology Research Group | ||
Full Title: A longitudinal study evaluating molecular changes associated with resistance to first and third (AZD9291) generation EGFR TKIs in patients with EGFR mutant NSCLC using "liquid biopsy" | ||
Medical condition: Patients with NSCLC | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004040-38 | Sponsor Protocol Number: SSCR105/NEAT33 | Start Date*: 2018-10-05 | |||||||||||
Sponsor Name:NEAT ID Foundation | |||||||||||||
Full Title: An open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with DTG+RPV FDC in antiretroviral treatment-experienced HIV-1 infected su... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) BE (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003755-41 | Sponsor Protocol Number: ERIS | Start Date*: 2021-10-12 |
Sponsor Name:Region Skåne | ||
Full Title: ERIS- EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study | ||
Medical condition: EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003814-16 | Sponsor Protocol Number: GS-US-200-4625 | Start Date*: 2020-03-31 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) FR (Completed) DE (Restarted) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016560-36 | Sponsor Protocol Number: NV22688 | Start Date*: 2010-07-27 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) ES (Completed) PL (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004070-26 | Sponsor Protocol Number: BRICE | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | |||||||||||||
Full Title: A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer a... | |||||||||||||
Medical condition: Advanced or metastatic epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to approved EGFR tyrosine kinase inhibitors (TKI); advan... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002710-74 | Sponsor Protocol Number: GS-US-292-1824 | Start Date*: 2015-11-24 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Inf... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002238-29 | Sponsor Protocol Number: NL49479.029.14 | Start Date*: 2014-12-18 |
Sponsor Name: | ||
Full Title: Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study | ||
Medical condition: NSCLC with EGFR mutation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000817-30 | Sponsor Protocol Number: TICTAC-2014 | Start Date*: 2014-08-14 |
Sponsor Name:University Medical Centre Utrecht | ||
Full Title: Comparing the effect of curcumin and genistein to treatment with Ivacaftor in CF patients with a class III mutation | ||
Medical condition: Cystic Fibrosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005492-12 | Sponsor Protocol Number: BDTX-189-01 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:Black Diamond Therapeutics, Inc. | |||||||||||||
Full Title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutation... | |||||||||||||
Medical condition: NSCLC, breast cancer, biliary tract cancer, or cervical cancer, any other solid tumors with specific gene mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) ES (Completed) IT (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004195-19 | Sponsor Protocol Number: CREPATS10 | Start Date*: 2020-07-07 | |||||||||||
Sponsor Name:Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS) | |||||||||||||
Full Title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma vire... | |||||||||||||
Medical condition: HIV disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002843-81 | Sponsor Protocol Number: 057 | Start Date*: 2020-01-07 |
Sponsor Name:IMEA | ||
Full Title: Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication | ||
Medical condition: HIV-1-infected patient Age > 65 years old Plasma HIV RNA ≤ 50 copies/mL for ≥ 6 months: one blip between 50 et 200 cp/ml is allowed in the last 6 months before screening. Currently receiving an ant... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000028-17 | Sponsor Protocol Number: MAINTAINAVIR | Start Date*: 2005-05-10 |
Sponsor Name:DAVID DALMAU | ||
Full Title: Eficacia virológica, inmunológica y trascendencia clínica del efecto de la lamivudina en pacientes portadores de la mutación M184V/I con fracaso terapéutico. | ||
Medical condition: HIV INFECTION | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001587-38 | Sponsor Protocol Number: FFCD1605 | Start Date*: 2017-12-21 |
Sponsor Name:Fédération Francophone de Cancérologie Digestive | ||
Full Title: A phase II study evaluating FOLFOX + panitumumab according to a "stop and go" strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line i... | ||
Medical condition: metastatic colorectal adenocarcinoma without a RAS mutation | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
